

台北榮民總醫院一般外科  
110年度醫學研究論文集

(科內刊物)



Annual Report 2021  
Division of General Surgery, Department of Surgery  
Taipei Veterans General Hospital  
School of Medicine, National Yang-Ming University

110年度一般外科(包括BCS)醫學論文  
Publication of Division of General Surgery in 2021

<Stomach>

1. Cardia gastric cancer is associated with increased PIK3CA amplifications and Hers expression than noncardia gastric cancer according to lauren classification.  
***Frontiers in Oncology. 2021;11:1-9.***  
Pai SM, Huang KH, Chen MH, Fang WL, Chao Y, Lo SS, Li Anna FY, Wu CW, Shyr YM.
2. Comparison of operative outcome among laparoscopic, 3d-laparoscopic, and robotic gastrectomy for distal gastric cancer.  
***International Surgery 2021;105:688-696.***  
Wu TY, Liu YL, Huang KH, Fang WL\*, Lo SS, Li Anna FY, Wu CW, Shyr YM.
3. Comparison of the long-term outcome between Billroth-I and roux-en-Y reconstruction following distal gastrectomy for gastric cancer.  
***Journal of Gastrointestinal Surgery. 2021;doi.org/10.1007/s11605-020-04867-1.***  
Wu CH, Huang KH, Chen MH, Fang WL, Chao Y, Lo SS, Li Anna FY, Wu CW, Shyr YM.
4. Differences in intestinal microbiota profiling after upper and lower gastrointestinal surgery.  
***Journal Chinese Medical Association 2021;doi:10.1097/JCMA.000000000000510.***  
Lin XH, Yang UC, Luo JC, Chang TE, Lin HH, Huang CW, Chiou JJ, Fang WL, Huang KH, Huang YH, Hou MC, Lee FY.
5. DNAJA3/Tid1 is required for mitochondrial DNA maintenance and regulates migration and invasion of human gastric cancer cells.  
***Cancers 2021;12:3463;doi:10.3390/cancers12113463.***  
Wang SD, Huang KH, Tseng WC, Lo JF, Li Anna FY, Fang WL, Chen CF, Yeh TS, Chang YL, Chou YC, Hung HH, Lee HC.
6. Genetic alterations in gastric cancer patients according to sex.  
***Aging. 2021;13:376-388.***  
Hsu LW, Huang KH, Chen MU, Fang WL, Chao Y, Lo SS, Li Anna F-Y, Wu CW, Shyr YM.
7. Multiple gastrointestinal metastases, small-bowel intussusception, and stomach polyps in advanced renal cell carcinoma: a case report and literature review.  
***Clinics in surgery 2021;6:1-3.***  
Yang SR, Fang WL, Li Anna FY, Huang KH.

8. The Associations between perioperative blood transfusion and long-term outcomes after stomach cancer surgery.  
***Cancer 2021;13:5438.***  
Hsu FK, Chang WK, Lin KJ, Liu CY, Fang WL, Chang KY.

<Liver>

1. ALBI grade in dialysis patients with hepatocellular carcinoma: prognostic impact and staging strategy.  
***Journal of Gastrointestinal Oncology. 2021;12:722-734.***  
Ho SY, Liu PH, Hsu CY, Ko CC, Huang YH, Su CW, Hsia CY, Lee RC, Hou MC, Huo TI.
2. A rare cause of a liver tumor nodule.  
***Gastroenterology 2021;3:663-665.***  
Chau IY, Chen YY, Chau GY.
3. Characterization of androgen receptor complex associated protein (ARCAP) in hepatocellular carcinoma and liver.  
***Journal Chinese Medical Association 2021;84:1100-1108.***  
Chang TJ, Hsia CY, Chau GY, Hsiao LT, Huang KT, King KL, Lui WY, Li Anna FY, Wang CL, Tsai PH, Chien Y, Lin TH.
4. Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy.  
***Journal of Formosa Medical Association 2021;120:1563-1571.***  
Wu CJ, Chau GY, Lee IC, Huo TI, Su CW, Hou MC, Huang YH.
5. Effect of primary tumor location on postmetastasectomy survival in patients with colorectal cancer liver metastasis.  
***Journal of Gastrointestinal Surgery 2021; 25:650-661.***  
Chen TH, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC, Cheng HH, Chau GY, Hsia CY, Lei HJ, Chou SC, Chao Y, Teng HW.
6. Evolutionary learning-derived clinical-radiomic models for predicting early recurrence of hepatocellular carcinoma after resection.  
***Liver Cancer 2021;10:572-582.***  
Lee IC, Huang JY, Chen TC, Yen CH, Chiu NC, Hwang HE, Huang JG, Liu CA, Chau GY, Lee RC, Hung YP, Chao Y, Ho SY, Huang YH.
7. Comparable benefits of HCV eradication by direct acting antivirals and interferon-based therapy in patients with hepatocellular carcinoma undergoing surgical resection.  
***American Journal of Cancer Research 2021;11:5526-5542.***  
Wu KC, Lee IC, Chi CT, Lei HJ, Chau GY, Yeh YC, Su CW, Huo TI, Chao Y, Lin HC, Hou MC, Huang YH.

8. Living donor liver transplantation for small infants aged less than 6 months the experience of a single institute.  
***Journal of Pediatric Surgery* 2021;56:1157-1161.**  
Yeh YT, Liu C, Tsai HL, Chen CY, Lin NC, Chang JW, Tsao PC, Lee YS, Hsia CY, Loong CC.
9. Hepatoma upregulated protein and Ki-67 expression in resectable hepatocellular carcinoma.  
***Journal Chinese Medical Association* 2021;84:623-632.**  
Lei HJ, Wang SY, Chau IY, Li Anna FY, Chau YP, Hsia CY, Chou SC, Kao YC, Chau GY.\*
10. Predictors of long-term recurrence and survival after resection of HBV-related hepatocellular carcinoma: the role of HBsAg.  
***American Journal of Cancer Research* 2021;11:3711-3725.**  
Lee IC, Lei HJ, Chau GY, Yeh YC, Wu CJ, Su CW, Huo TI, Chao Y, Hou MC, Huang YH.
11. Surgical management of intrahepatic cholangiocarcinoma: a narrative review.  
***Digestive Medical Research* 2021;4:4.**  
Lei HJ\*, Shyr YM, Hsia CY, Chen MH, Huang YH, Chau GY.
12. The role of albumin-bilirubin grade in determining the outcomes of patients with very early-stage hepatocellular carcinoma.  
***Journal Chinese Medical Association* 2021;84:136-143.**  
Chang CY, Wei CY, Chen PH, Hou MC, Chao Y, Chau GY, Lee RC, Huang YH, Su YH, Wu JC, Su CW.

#### <Breast>

1. A phase Ib study of alpelisib or buparlisib combined with tamoxifen plus goserelin in premenopausal women with HR positive HER2-negative advanced breast cancer.  
***Clinical Cancer Research* 2021;27:408-417.**  
Lu YS, Lee KS, Chao TY, Tseng LM, Chitapanarus I, Chen SC, Liu CT, Sohn J, Lim JH, Chang YV, Yang Y, et al.
2. Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens.  
***Breast Cancer Res Treat.* 2021 Oct;189(3):665-676. doi: 10.1007/s10549-021-06313-5. Epub 2021 Sep 23.**
3. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY Trial: 6 Years' follow-up.

*Journal of Clinical Oncology. 2021;37:1448-1459.*

Piccart M, Procter M, Fumagalli D, Azambuja E, MSc EC, Ewer MS, Restuccia E, Jerusalem G, Tseng LM, et al.

4. Clinicopathological characteristics and treatment outcomes of luminal B1 breast in Tawan.  
*Journal Chinese Medical Association 2021;Oct 8. Doi:1097/JCMA.0000000000632. Online ahead of print.*  
Chen BF, Tsai YF, Huang CC, Hsu CY, Lien PJ, Wang YL, Lin YS, Feng CJ, King KL, Chiu JH, Chau GY, Tseng LM.
5. Clinical outcomes and metastatic behavior between de novo versus recurrent Her2-positive metastatic breast cancer: a 17-year single-institution cohort study at Taipei Veterans General Hospital.  
*Journal Chinese Medical Association 2021;Oct 8. Doi:1097/JCMA.0000000000622. Online ahead of print.*  
Chen HF, Tsai YF, Huang CC, Lien PJ, Wang YL, Hsu CY, Chen YJ, Liu CY, Chao TC, Lin YS, Feng CJ, Chiu JH, Chau GY, Tseng LM.
6. Clinical impacts of molecular subtyping by multigene assay on hormone receptor positive breast cancers.  
**Jouranl of Chinese Medicine Association. 2021;doi: 10.1097/JCMA.000000000000657.** Epub ahead of print.  
Liu YL, Hsu CY, Feng CJ, Lien PJ, Huang CC, Lin YS, Wang YL, Chao TC, Liu CY, Chiu JH, Tsai YF\*, Tseng LM.
7. Chemotherapy- induced peripheral neuropathy in newly diagnosed breast cancer survivors treated with taxane: a prospective longitudinal study.  
*Support Care Cancer. 2021 Jun; 29(6):2959-2971.*  
Wang YJ, Chan YN, Jheng YW, Wu CJ, Lin MW, Tseng LM, Tsai YF, Liu LC.
8. Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses.  
*BMC Cancer. 2021;21:199. doi: 10.1186/s12885-021-07931-4.*  
Huang CC, Tsai YF, Liu CY, Chao TC, Lien PJ, Lin YS, Feng CJ, Chiu JH, Tseng LM.
9. Expression pattern and prognostic impact of glycoprotein non-metastatic B (GPNMB) in triple-negative breast cancer.  
*Scientific Reports 2021;11:12171.*  
Huang YH, Chu PY, Chen JL, Husng CT, Huang CC, Tasi YF, Wang YL, Lien PJ, Tseng LM, Liu CY.
10. VGH-TAYLOR: Comprehensive precision medicine study protocol on the heterogeneity of Taiwanese breast cancer patients.  
*Future Oncology 2021;17:4-57-4069.*

Liu CY, Huang CC, Tsai YF, Chao TC, Lien PJ, Lin YS, Feng CJ, Chen JL, Chen YJ, Chiu JH, Hsu CY, Tseng LM.

11. Developing a Web-Based Shared Decision-Making Tool for Fertility Preservation Among Reproductive-Age Women With Breast Cancer: An Action Research Approach.  
***Journal of Medical Internet Research.* 2021;23:e24926. doi: 10.2196/24926.**  
Tseng LM, Lien PJ, Huang CY, Tsai YF, Chao TC, Huang SM.
12. Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation  
***Nature Communications.* 2021;12:2788. doi: 10.1038/s41467-021-23075-2.**  
Lee HH, Wang YN, Yang WH, Xia W, Wei Y, Chan LC, Wang YH, Jiang Z, Xu S, Yao J, Qiu Y, Hsu YH, Hwang WL, Yan M, Cha JH, Hsu JL, Shen J, Ye Y, Wu X, Hou MF, Tseng LM, et al.
13. Influence of treatment Chinese medicine on medical adherence and outcome in estrogen receptor(+) breast cancer patients in Taiwan: a real-world population-based cohort study.  
***Phytomedicine* 2021;80:153365.**  
Chan PW, Chiu JH, Huang N, Chen CM, Yu H, Liu CY, Hsu CH.
14. Interleukin 17A promotes cell migration, enhances anoikis resistance, and creates a microenvironment suitable for triple negative breast cancer tumor metastasis.  
***Cancer Immunology Immunotherapy.* 2021. doi: 10.1007/s00262-021-02867-x.**  
Tsai YH, Huang CC, Lin YS, Hsu CY, Huang CP, Liu CY, Chiu JH\*\*, Tseng LM.
15. Molecular subtyping of breast cancer intrinsic taxonomy with oligonucleotide microarray and nanostring ncounter.  
***Bioscience Reports* 2021;41:BSR20211428. doi: 10.1042/BSR20211428.**  
Chen YJ, Huang CS, Phan NN, Lu TP, Liu CY, Huang CJ, Chiu JH, Tseng LM, Huang CC.
16. Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study.  
***Japanese Journal of Clinical Oncology.* 2021;51:345-353.**  
Shao Z, Tseng LM, Huang CS, Pang D, Yang Y, Li W, Liao N, Geng C, Zhang Q, Xu B, Liu D, Kwong A et al.
17. Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study.  
***Breast Cancer Research Treatment.* 2021;187:759-768.**  
Huang CS, Yang YY, Kwong A, Chen SC, Tseng LM, Liu MC, Shen KS, Wang S, Ng TY, Feng Y, Sun G, Yan IR, Shao Z.
18. Residual risk stratification of Taiwanese breast cancers following curative therapies with the extended concurrent genes signature

***Breast Cancer Research and Treatment* 2021;186:475-485.**

Huang CS, Lu TP, Liu CY, Huang CJ, Chiu JH, Chen YJ, Tseng LM\*\*, Huang CC.

19. Self-care as a mediator between symptom-management self-efficacy and quality of life in women with breast cancer.

***PLoS One.* 2021;16:e0246430. doi: 10.1371/journal.pone.0246430.**

Chin CH, Tseng LM, Chao TC, Wang TJ, Wu SF, Liang SY.

20. Salubrinal Enhances Cancer Cell Death during Glucose Deprivation through the Upregulation of xCT and Mitochondrial Oxidative Stress.

***Biomedicines.* 2021 ;9:1101. doi: 10.3390/biomedicines9091101.**

Chen MC, Hsu LL, Wang SF, Pan YL, Lo JF, Yeh TS, Tseng LM, Lee HC.

21. Targeted Sequencing of Taiwanese Breast Cancer with Risk Stratification by the Concurrent Genes Signature: A Feasibility Study.

***Journal of Personalized Medicine.* 2021;11:613. doi: 10.3390/jpm11070613.**

Huang CS, Liu CY, Lu TP, Huang CJ, Chiu JH, Tseng LM, Huang CC.

#### <Pancreas>

1. Comparative study of pancreas transplantation between type 1 and 2 diabetes mellitus.

***HepatoBiliary Surgical Nutrition.* 2021;10:443-453.**

Shyr BS, Shyr BU, Chen SC, Loong CC, Shyr YM, Wang SE.

2. Circulating cell-free DNA as a prognostic biomarker in resectable ampullary cancer.

***Cancers.* 2021;13:1-9.**

Shyr BU, Shyr BS, Chen SC, Chang SC, Shyr YM, Wang SE.

3. Circulating cell-free DNA in pancreatic head adenocarcinoma undergoing pancreaticoduodenectomy.

***Pancreas.* 2021;00:1-5.**

Wang SE, Shyr BU, Shyr BS, Chen SC, Chang SC, Shyr YM.

4. Inferior survival outcomes of pancreas transplant alone in urine patients.

***Scientific Reports* 2021; 11:21073.**

Shyr BU, Shyr BS, Chen SC, Chang SC, Shyr YM, Wang SE.

5. Mesopancreas level 3 dissection in robotic pancreaticoduodenectomy.

***Surgery* 2021;169:362-368.**

Shyr BU, Shyr BS, Chen SC, Shyr YM, Wang SE.

6. Preventive covered stent placement at the gastroduodenal artery stump in angiogram-negative sentinel hemorrhage after pancreaticoduodenectomy.

***Abdomen Radiology* 2021, 46:4995-5006.**

Lin YM, Lin WY, Tseng HS, Lee RC, Huang HE, Wang SE, Shyr YM, Liu CA.

7. Propensity score-matched comparison of the oncological feasibility and survival outcomes for pancreatic adenocarcinoma with robotic and open pancreatoduodenectomy.  
***Surgical Endoscopy* 2021;doi.org/10.1007/s00464-021-084377-7.**  
Shyr BU, Shyr BS, Chen SC, Shyr YM, Wang SE.
8. Robotic pancreaticoduodenectomy for pancreatic head cancer and periampullary lesions.  
***Annals Gastroenterology Surgery* 2021;5:589-596.**  
Shyr YM, Wang SE, Chen SC, Shyr BU, Shyr BS.
9. Robotic and open pancreaticoduodenectomy: results from Ttaipei Veterans General Hospital in Taiwan.  
***Updates Surgery* 2021, 73:939-946.**  
Shyr BU, Shyr BS, Chen SC, Shyr YM, Wang SE.
10. Surgical and survival outcomes after robotic and open pancreaticoduodenectomy with positive margins.  
***Journal Chinese Medical Association* 2021; doi.org/10.1097/JCMA.0000000000558.**  
Lee PY, Shyr BU, Shyr BS, Chen SC, Shyr YM, Wang SE.

<Other>

1. Diabetes is the most critical risk factor of adverse complications after peritoneal dialysis catheter placement.  
***Frontiers in Medicine* 2021;8:doi:20.3389/fmed.2021.719345.**  
Chang HH, Chang CH, Hsiao CY, Kao SY, Chen JY, Chen TH, Tsai PJ.
2. Living donor liver transplantation for small infants aged less than 6 months: the experience of a single institute.  
***Journal of Pediatric Surgery*. 2021;56:1157-1161.**  
Yeh YT, Liu C, Tsai HL, Chen CY, Lin NC, Chang JW, Tsao PC, Lee YS, Hsia CY, Loong CC.



Table 1. Paper Publications Included in Science Citation Index in 2021

	Impact factor	Rank Field	No. of Papers
Abdominal Radiology	3.039	6/133	1
Aging-US	5.682	67/195	1
American Journal of Cancer Research	6.166	64/242	2
Annals of Gastroenterology Surgery	5.164	31/92	1
Biomedicines	4.757	62/139	1
Bioscience Reports	3.976	165/296	1
BMC Cancer	4.638	109/245	1
Breast Cancer Research Treatment	4.624	110/245	3
Cancers	6.639	51/242	3
Cancer Immunology Immunotherapy	6.630	58/245	1
Clinics in Surgery	2.373	80/92	1
Clinical Cancer Research	2.530	103/211	1
Digestive Medicine Research	2.379	16/39	1
Frontier in Oncology	6.244	62/242	1
Frontier in Medicine	5.093	28/167	1
Future Oncology	3.674	149/245	1
Gastroenterology	22.682	4/92	1
Hepatobiliary Surgery and Nutrition	7.293	19/92	1
International Surgery	0.056	209/210	1
Japanese Journal of Clinical Oncology	2.925	183/245	1
Journal of Clinical Oncology	50.769	6/245	1
Journal of Gastrointestinal Oncology	2.587	79/93	1
Journal of Gastrointestinal Surgery	3.452	58/92	2
Journal of the Chinese Medical Association	2.743	62/167	8
Journal of the Formosan Medical Association	3.282	53/167	1
Journal of Medical Internet Research	7.093	10/109	1
Journal of Pediatric Surgery	2.545	102/211	2
Journal of Personalized Medicine	3.508	69/172	1
Liver Cancer	6.166	64/242	1
Nature Communications	17.694	6/73	1
Scientific Reports	4.380	17/72	2
Surgery	3.982	45/211	1
Surgical Endoscopy	4.584	33/211	1
Support Care Cancer	3.359	164/245	1
Pancreas	3.327	61/92	1
Phytomedicine	6.656	7/63	1
PLOS One	3.752	29/73	1
Updates in Surgery	2.797	82/211	1
Total			53

Table 2. Paper Publications not Included in Science Citation Index in 2021

Total	0
-------	---

Table 3. Publications According to Organs in 2021

Organs	Stomach	Liver	Pancreas &Biliary	Breast	Thyroid	Transplan- tation	Miscell- aneous
SCI	8	12	10	21	0	1	1
Non-SCI	0	0	0	0	0	0	0
Total	8	12	10	21	0	1	1

SCI=Science citation index

Table 4. Publications According to Whether the First Author/Corresponding Authors of the Paper Being Member of the Division of General Surgery in 2021

Authors	First author/corresponding author being member of General Surgery	
	yes	no
SCI	23	30
Non-SCI	0	0
Total	23	30

SCI=Science citation index




Figure 1. Number of publications in years 2017-2021




Figure 2. Number of publications according to whether the first/corresponding authors being member of the Division of General Surgery in years 2017-2021




Figure 3-1. Number of SCI publications according to organs in years 2017-2021




Figure 3-2. Number of Non-SCI publications according to organs in years 2017-2021

